Literature DB >> 33830561

Ferumoxytol-enhanced magnetic resonance T1 reactivity for depiction of myocardial hypoperfusion.

Caroline M Colbert1, Anna H Le2, Jiaxin Shao3, Jesse W Currier2, Olujimi A Ajijola2,4, Peng Hu1,3, Kim-Lien Nguyen1,2,3.   

Abstract

Myocardial T1 reactivity, defined as the relative change in T1 between rest and vasodilator-induced stress, has been proposed as a magnetic resonance imaging (MRI) biomarker of tissue perfusion. We hypothesize that the superparamagnetic iron-oxide nanoparticle, ferumoxytol, sensitizes T1 to changes in the intramyocardial vascular compartment and improves the sensitivity and specificity of T1 reactivity as an imaging biomarker of tissue perfusion. We aim to assess the diagnostic performance of ferumoxytol-enhanced (FE) myocardial T1 reactivity in swine models of myocardial hypoperfusion. We induced acute myocardial hypoperfusion in 13 swine via percutaneous, transcatheter deployment of a 3D printed intracoronary stenosis implant into the left anterior descending coronary artery. We performed native and FE adenosine stress testing using 5(3)3(3)3 MOLLI and SASHA T1 mapping sequences with bSSFP readout on a clinical 3.0 T magnet. MOLLI T1 maps were fitted using both the conventional MOLLI and the Instantaneous Signal Loss (InSiL) T1-fitting algorithms. Regardless of the MOLLI or SASHA pulse sequence or T1-fitting algorithm, ferumoxytol contrast increased the dynamic range of T1 reactivity in both the remote and ischemic myocardial regions. Relative to remote myocardium, native and FE T1 reactivity were blunted in ischemic myocardium (p < 0.05) with InSiL-MOLLI, MOLLI and SASHA. An InSiL-MOLLI-derived FE T1 reactivity threshold of -4.65% had 73.3% sensitivity and 96.2% specificity for prediction of regional wall motion abnormalities (AUC 0.915, 95% CI 0.786-0.979), whereas a SASHA-derived FE T1 reactivity threshold of -5.25% had 75.0% sensitivity and 95.2% specificity (AUC 0.905, 95% CI 0.751-0.979). Ferumoxytol significantly increased the dynamic range of T1 reactivity as a measure of myocardial hypoperfusion in vasodilator stress T1 mapping studies. FE T1 reactivity maps can be used to quantitatively distinguish ischemic and remote myocardium with high specificity in swine models of acute myocardial hypoperfusion.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  animal model study; iron-based and other contrast agents; ischemic heart diseases; myocardial perfusion; relaxometry

Mesh:

Substances:

Year:  2021        PMID: 33830561      PMCID: PMC8287706          DOI: 10.1002/nbm.4518

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.478


  42 in total

Review 1.  Gadolinium-based contrast agents: A comprehensive risk assessment.

Authors:  Tyler J Fraum; Daniel R Ludwig; Mustafa R Bashir; Kathryn J Fowler
Journal:  J Magn Reson Imaging       Date:  2017-01-13       Impact factor: 4.813

2.  elastix: a toolbox for intensity-based medical image registration.

Authors:  Stefan Klein; Marius Staring; Keelin Murphy; Max A Viergever; Josien P W Pluim
Journal:  IEEE Trans Med Imaging       Date:  2009-11-17       Impact factor: 10.048

3.  Instantaneous signal loss simulation (InSiL): an improved algorithm for myocardial T₁ mapping using the MOLLI sequence.

Authors:  Jiaxin Shao; Kim-Lien Nguyen; Yutaka Natsuaki; Bruce Spottiswoode; Peng Hu
Journal:  J Magn Reson Imaging       Date:  2014-02-19       Impact factor: 4.813

4.  Leakage and water exchange characterization of gadofosveset in the myocardium.

Authors:  Octavia Bane; Daniel C Lee; Brandon C Benefield; Kathleen R Harris; Neil R Chatterjee; James C Carr; Timothy J Carroll
Journal:  Magn Reson Imaging       Date:  2013-12-07       Impact factor: 2.546

Review 5.  Gadolinium deposition in the brain: summary of evidence and recommendations.

Authors:  Vikas Gulani; Fernando Calamante; Frank G Shellock; Emanuel Kanal; Scott B Reeder
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

6.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

7.  Ferumoxytol-Enhanced CMR for Vasodilator Stress Testing: A Feasibility Study.

Authors:  Kim-Lien Nguyen; Jiaxin Shao; Vahid K Ghodrati; Olujimi A Ajijola; Rohan Dharmakumar; J Paul Finn; Peng Hu
Journal:  JACC Cardiovasc Imaging       Date:  2019-03-13

8.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold.

Authors:  Stefan K Piechnik; Vanessa M Ferreira; Erica Dall'Armellina; Lowri E Cochlin; Andreas Greiser; Stefan Neubauer; Matthew D Robson
Journal:  J Cardiovasc Magn Reson       Date:  2010-11-19       Impact factor: 5.364

Review 9.  State-of-the-art review: stress T1 mapping-technical considerations, pitfalls and emerging clinical applications.

Authors:  Stefan K Piechnik; Stefan Neubauer; Vanessa M Ferreira
Journal:  MAGMA       Date:  2017-09-15       Impact factor: 2.310

Review 10.  Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.

Authors:  Robert J McDonald; Deborah Levine; Jeffrey Weinreb; Emanuel Kanal; Matthew S Davenport; James H Ellis; Paula M Jacobs; Robert E Lenkinski; Kenneth R Maravilla; Martin R Prince; Howard A Rowley; Michael F Tweedle; Herbert Y Kressel
Journal:  Radiology       Date:  2018-09-11       Impact factor: 11.105

View more
  1 in total

1.  Myocardial blood flow is the dominant factor influencing cardiac magnetic resonance adenosine stress T2.

Authors:  Jill J Weyers; Venkat Ramanan; Ahsan Javed; Jennifer Barry; Melissa Larsen; Krishna Nayak; Graham A Wright; Nilesh R Ghugre
Journal:  NMR Biomed       Date:  2021-11-17       Impact factor: 4.044

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.